Risk Classification for Large Cell Lymphoma using Lactate Dehydrogenase, Beta-2 Microglobulin, and Thymidine Kinase

References

• Ellims P. H., Gan E., Medley G., Van Der Weyden M. B. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. Blood 1981; 58(5)926–930
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Dick F. R., Corder M. P., Garneau S. C., Platz C. E., Slymen D. J. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophos-phamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1982; 50: 1695–1702
   PubMed Web of Science ®Google Scholar
• Gronowitz J. S., Hagberg H., Kallendar C., Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br. J. Cancer 1983; 47: 487–495
   PubMed Web of Science ®Google Scholar
• Hagberg H., Killander A., Simonsson B. Serum B2 microglobulin in malignant lymphoma. Cancer 1983; 51: 2220–2225
   PubMed Web of Science ®Google Scholar
• Hagberg H., Glimelius B., Gronowitz S. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and Prognosis: A multivariate analysis. Scand. J. Haematol 1984; 33: 59–67
   PubMedGoogle Scholar
• Koziner B., Sklaroff R., Little C., Labriola D., Thaler H. T., Strauss D. J., Young C. W., Nisce L. Z., Oettgen H., Lee B. J., III., Clarkson B. D. NHL-3 protocol: six drug combination chemotherapy for non-Hodgkin's lymphoma. Cancer 1984; 53: 2592–2600
   PubMed Web of Science ®Google Scholar
• Steward W., Todd D. H., Harris M., Jones J. M., Blackledge G., Waeptaff J., Anderson H., Wilkinson P. M., Crowther D. A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma. Eur. J. Cancer Clin. Oncol 1984; 20(7)881–889
   PubMedGoogle Scholar
• Jagannath S., Velasquez W. S., Tucker S. L., Fuller L. M., McLaughlin P. W., Manning J. T., North L. B., Cabanillas F. C. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large cell lymphoma. J. Clin. Oncol 1986; 4(6)859–865
   PubMed Web of Science ®Google Scholar
• Amlot P., Adinolfi M. Serum B2 microglobulin and its prognostic value in lymphoma. Europ. J. Cancer 1987; 15: 791–796
   Web of Science ®Google Scholar
• Canellos G. P., Skarin A. T., Klatt M. M. The m-BACOD combination chemotherapy regimen in the treatment of diffuse-large cell lymphoma. Semin. Hematol 1987; 24: 2–7, (Suppl I).
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. M. Updated clinical experience with MACOP-B. Semin. Hematol 1987; 24: 26–24, (Suppl I).
   PubMed Web of Science ®Google Scholar
• Hallek K. M., Emmerich B., Strohmeyer S. Activity of serum thymidine kinase in non-Hodgkin's lymphoma: Relationship to other prognostic factors. Klin. Wochensher 1988; 66: 718–723
   PubMedGoogle Scholar
• Martinsson U., Glimelius B., Hagberg H., Sundström C. Prognostic relevance of serum markers in relation to histopathology, stage, and initial symptoms in advanced low-grade non-Hodgkin's lymphomas. Eur. J. Haematol 1988; 40: 289–298
   PubMed Web of Science ®Google Scholar
• Coffier B., Gisselbrecht C., Herbrecht R., Tilly H., Bosly A., Brousse N. LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J. Clin. Oncol 1989; 7: 1018–1026
   PubMed Web of Science ®Google Scholar
• Cowan R. A., Jones M., Harris M., Steward W. P., Radford J. A., Wagstaff J., Deadin D. P., Crowther D. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br. J. Cancer 1989; 59: 276–282
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Hoskins P., Klimo P., Connors J. M. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann. Oncol 1991, 2: 17–21, Suppl 1
   PubMedGoogle Scholar
• Rossi G., Mariano M. R., Arcangeli G., Bonfanti V., Capucci M. A., Ferremi P., Marpicati P., Meriggi F., Zaniboni A., Izzi T., Marini G. A phase II trial of ProMACE-CytaBOM in previously untreated non-Hodgkin's lymphoma of intermediate- or high-grade histology. Hemat. Oncol 1991; 9: 147–155
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Fuller L., Jagannath S., Tucker S. L., North L. B., Hagemeister G. B., McLaughlin P., Swan F., Redman J. R., Rodriguez M. A., Cabanillas F. Stages I and II diffuse large cell lymphomas: Prognostic factors and long-term results with CHOP-Bleo and Radiotherapy. Blood 1991; 77(5)942–947
   PubMed Web of Science ®Google Scholar
• Hallek M., Wanders I., Strohmeyer S., Emmerich B. Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann. Hematol 1992; 65: 1–5
   PubMed Web of Science ®Google Scholar
• Danieu L., Wong G., Kozimer B., Clarkson B. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res 1986; 46: 5372–5379
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pinkus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Canellos G. P. Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann. Intern. Med 1986; 104: 757–765
   PubMed Web of Science ®Google Scholar
• Swan F., Velasquez W. S., Tucker S. A new serologic staging system for large-cell lymphomas based on initial B2 microglobulin and lactate dehydrogenase levels. J. Clin. Oncol 1989; 7(10)1518–1527
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Jagannath S., Tucker S., Fuller L. M., North L. B., Redman J. R., Swan F., Hagemeister G. B., McLaughlin P., Cabanillas F. Risk classification as the basis for clinical staging of diffuse large cell lymphoma derived from 10-year survival data. Blood 1989; 74(2)551–557
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J. M., Tilly H., Herbrecht R., Bosly A., Armitage J. O. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol 1991; 9(2)211–219
   PubMed Web of Science ®Google Scholar
• Rodriguez J., Cabanillas F., McLaughlin P., Swan F., Rodriguez M., Hagemeister F., Romaguera J. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the `tumor score'. Ann. Oncol 1992; 3: 711–717
   PubMed Web of Science ®Google Scholar
• Jones S. E., Miller T. P., Connors J. M. Long-term follow-up and analysis for prognostic factors for patients with limited stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J. Clin. Oncol 1989; 7: 1186–1191
   PubMed Web of Science ®Google Scholar
• Longo D. L., Glatstein E., Duffey P. L., Ihde D. C., Hubbard S. M., Fisher R. I., Jaffe E. S., Gilliom M., Young R. C., DeVita V. T., Jr. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved field radiation therapy. J. Clin. Oncol 1989; 7: 1295–1302
   PubMed Web of Science ®Google Scholar
• Chadha M., Shank B., Fuks Z., Clarkson D. B., Bonfiglio P., Gnecco C., Gulati S. Improved survival of poor prognosis diffuse histiocytic (large cell) lymphoma managed with sequential induction chemotherapy, “boost” radiation therapy, and autologous bone marrow transplantation. Int. J. Radiat. Oncol. Biol. Phys 1988; 14: 407–415
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Shank B., Black P., Yopp J., Koziner B., Straus D., Filippa D., Kempin S., Castro-Malaspina H., Cunningham I., Berman E., Coleman M., Langleben A., Colvin O. M., Fuks Z., O'Reilly R., Clarkson B. Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J. Clin. Oncol 1988; 6: 1303–1313
   PubMed Web of Science ®Google Scholar
• Dixon D., McLaughlin P., Hagemeister F., Freireich E. J., Fuller L. M., Cabanillas F. C., Gehan E. A. Reporting outcomes in Hodgkin's disease and lymphoma. J. Clin. Oncol 1987; 5: 1670–1672
   PubMed Web of Science ®Google Scholar
• Kaplan E., Meier P. Non-parametric estimation from incomplete observations. J. Am. Statistical Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R., Pike M. conservatism of the approximation (0 - E)2/E in the log rank for survival data on tumor incidence data. Biometrics 1973; 29: 579–584
   PubMed Web of Science ®Google Scholar
• Cox D. R. Regression models and live tables. J. R. Stat. Soc. Series B 1972; 34: 187
   Web of Science ®Google Scholar
• Bello J. L. Regulation of thymidine kinase synthesis in human cells. Exp. Cell. Res 1974; 89: 263–274
   PubMed Web of Science ®Google Scholar
• Kit S. Virol-associated and induced enzymes. Pharmacol. Ther 1979; 4: 501–585
   Web of Science ®Google Scholar
• Lehtiman T. Correlation between tumor proliferation and serum levels of B2-microglobulin and thymidine kinase in malignant lymphomas. Cancer Det. and Prev 1988; 12: 125–131
   PubMedGoogle Scholar
• Simonsson B., Kallander C. F. R., Brenning G. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br. J. Haematol 1985; 6: 215–224
   Web of Science ®Google Scholar
• Drexler H. G., Gaedicke G., Minowada J. Isoenzyme studies in human leukemia-lymphoma cell lines—IV lactate dehydrogenase. Leuk Res 1985; 9: 561–571
   PubMed Web of Science ®Google Scholar
• Vezzoni M. A., Giardini R., Raineri Pozzi M. R., Lucchini R., Vezzoni M. A., Clerici L., Besana C., Rugarli C., Rilke F. Relation between enzymatic activities and the degree of malignancy of human lymphomas. Eur. J. Cancer Clin. Oncol 1985; 21: 945–950
   PubMedGoogle Scholar
• Swan F., Ordonez N., Manning J. B2-microglobulin cell surface expression as an indicator of resistance in lymphoma cells and its relation to the serum level. Proc. Amer. Soc. Hematol 1988; 72: 258a, (Abstract)
   Google Scholar